XKRX:001067 (Korea (the Republic of))
Â
Pfd Shs Non-Voting
â‚©
44,050
-950 (-2.11%)
Aug 18
Business Description
JW Pharmaceutical
ISIN : KR7001062009
Share Class Description:
XKRX:001067: Pfd Shs Non-VotingTotal Employee Number:
1,087Compare
Compare
Traded in other countries / regions
001060.Korea Index Membership
KOSPI IPO Date
1976-06-14Description
JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.23 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | 0.44 | |||||
Interest Coverage | 288.76 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 4.17 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.2 | |||||
3-Year EBITDA Growth Rate | 18.3 | |||||
3-Year EPS without NRI Growth Rate | 21.5 | |||||
3-Year FCF Growth Rate | 12.8 | |||||
3-Year Book Growth Rate | 16.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.23 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.09 | |||||
9-Day RSI | 53.95 | |||||
14-Day RSI | 52.36 | |||||
3-1 Month Momentum % | -18.11 | |||||
6-1 Month Momentum % | -27.67 | |||||
12-1 Month Momentum % | -29.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.46 | |||||
Quick Ratio | 0.92 | |||||
Cash Ratio | 0.31 | |||||
Days Inventory | 102.04 | |||||
Days Sales Outstanding | 55.97 | |||||
Days Payable | 54.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.44 | |||||
Dividend Payout Ratio | 0.22 | |||||
Forward Dividend Yield % | 1.44 | |||||
5-Year Yield-on-Cost % | 1.44 | |||||
3-Year Average Share Buyback Ratio | 0.7 | |||||
Shareholder Yield % | 10.03 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.29 | |||||
Operating Margin % | 13.42 | |||||
Net Margin % | 9.05 | |||||
EBITDA Margin % | 15.69 | |||||
FCF Margin % | 6.44 | |||||
OCF Margin % | 10.8 | |||||
ROE % | 20.32 | |||||
ROA % | 11.77 | |||||
ROIC % | 18.43 | |||||
3-Year ROIIC % | -84.56 | |||||
ROC (Joel Greenblatt) % | 43.72 | |||||
ROCE % | 26.89 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 9.53 | |||||
Forward PE Ratio | 11.85 | |||||
PE Ratio without NRI | 9.53 | |||||
Shiller PE Ratio | 41.65 | |||||
Price-to-Owner-Earnings | 7.94 | |||||
PEG Ratio | 0.21 | |||||
PS Ratio | 0.85 | |||||
PB Ratio | 1.72 | |||||
Price-to-Tangible-Book | 2.1 | |||||
Price-to-Free-Cash-Flow | 13.31 | |||||
Price-to-Operating-Cash-Flow | 8.04 | |||||
EV-to-EBIT | 6.15 | |||||
EV-to-EBITDA | 5.2 | |||||
EV-to-Revenue | 0.81 | |||||
EV-to-FCF | 12.93 | |||||
Price-to-GF-Value | 0.74 | |||||
Price-to-Projected-FCF | 0.84 | |||||
Price-to-Median-PS-Value | 0.71 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.38 | |||||
Price-to-Graham-Number | 0.94 | |||||
| Price-to-Net-Current-Asset-Value | 10.03 | |||||
Earnings Yield (Greenblatt) % | 16.27 | |||||
FCF Yield % | 7.8 | |||||
Forward Rate of Return (Yacktman) % | 25.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
JW Pharmaceutical Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 789,946.548 | ||
| EPS (TTM) (â‚©) | 2962 | ||
| Beta | -0.0584 | ||
| 3-Year Sharpe Ratio | -1.2 | ||
| 3-Year Sortino Ratio | -1.22 | ||
| Volatility % | 16.62 | ||
| 14-Day RSI | 52.36 | ||
| 14-Day ATR (â‚©) | 925.492578 | ||
| 20-Day SMA (â‚©) | 43412.5 | ||
| 12-1 Month Momentum % | -29.89 | ||
| 52-Week Range (â‚©) | 38500 - 63300 | ||
| Shares Outstanding (Mil) | 23.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
JW Pharmaceutical Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
JW Pharmaceutical Stock Events
| Event | Date | Price (â‚©) | ||
|---|---|---|---|---|
| KRW 650.000000 Cash Dividend | 2026-03-31 | 56,000.00 (+0.00%) | ||
| KRW 450.000000 Cash Dividend | 2024-12-27 | 58,700.00 (-2.81%) | ||
| 1.02:1 Stock Split | 2023-12-27 | 60,980.39 (+0.32%) | ||
| 1.03:1 Stock Split | 2023-03-13 | 55,872.83 (+0.00%) | ||
| 1.03:1 Stock Split | 2021-12-29 | 55,816.46 (+0.67%) | ||
| 1.03:1 Stock Split | 2020-12-29 | 48,089.80 (-0.37%) | ||
| 1.02:1 Stock Split | 2017-12-27 | 38,086.92 (+0.58%) | ||
| 1.02:1 Stock Split | 2016-12-28 | 34,839.28 (+1.00%) | ||
| 1.05:1 Stock Split | 2015-12-29 | 35,562.02 (-9.60%) | ||
| 1.05:1 Stock Split | 2014-12-29 | 12,749.61 (-1.81%) |
Show
Entries
JW Pharmaceutical Frequently Asked Questions
What is JW Pharmaceutical(XKRX:001067)'s stock price today?
The current price of XKRX:001067 is â‚©44050.00. The 52 week high of XKRX:001067 is â‚©63300.00 and 52 week low is â‚©38500.00.
When is next earnings date of JW Pharmaceutical(XKRX:001067)?
The next earnings date of JW Pharmaceutical(XKRX:001067) is .
Does JW Pharmaceutical(XKRX:001067) pay dividends? If so, how much?
The Dividend Yield %  of JW Pharmaceutical(XKRX:001067) is 1.44% (As of Today), Highest Dividend Payout Ratio of JW Pharmaceutical(XKRX:001067) was 4.85. The lowest was 0.17. And the median was 0.26. The  Forward Dividend Yield % of JW Pharmaceutical(XKRX:001067) is 1.44%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on JW Pharmaceutical
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers